Loading...

Sanofi says its Covid vaccine candidate yields positive trial data

| Updated: June 24, 2022 16:34:36


A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition centre in Paris, France on June 15, 2022 — Reuters photo A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition centre in Paris, France on June 15, 2022 — Reuters photo

Sanofi's Covid-19 vaccine candidate, which is modelled on the virus's Beta antigen, delivered 72 per cent efficacy in adults against the Omicron strain, the French drugmaker said on Friday, citing data gathered in a study.

"Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," the firm, which is developing the vaccine jointly with Britain's GSK, said in a statement, reports Reuters.

The new data supporting its booster vaccine will be submitted to regulatory authorities, Sanofi added, reiterating its plan to start marketing its jab later this year.

Share if you like